Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 17/07/2024 BST			After market 22:34:32
156.6 ^USD	+3.69%		156.7	+0.08%

11:05pm	Dow Closes at Record, Nasdaq Slides as Markets Parse Fed Governor Remarks, Earnings	MT
10:28pm	Dow Closes at Record High as Nasdaq Plunges; Markets Parse Fed Governor Remarks, Earnings, Trade Threats	MT

Johnson & Johnson : Second Quarter 2024 2Q24 Other Financial Disclosures

July 17, 2024 at 11:30 am

Second Quarter 2024

Other Financial Disclosures

Table of Contents

Table 1: Sales by Segment	1
Table 2: Sales by Geographic Area	2
Table 3: Sales of Key Products/Franchises	3 - 7
Table 3a: Supplemental Sales Reconciliation	8
Table 4: Condensed Consolidated Statement of Earnings - QTD	9
Table 5: Condensed Consolidated Statement of Earnings - YTD	10
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD	11
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD	12
Table 8: Non-GAAP Adjusted Net Earnings	13
Table 9: Non-GAAP IBT and R&D Expense by Segment - QTD	14
Table 10: Non-GAAP IBT and R&D Expense by Segment - YTD	15
Table 11: Non-GAAP P&L Reconciliation	16

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)				SECOND QUARTER
						Percent Change
		2024	2023	Total		Operations	Currency
Sales to customers by
segment of business
Innovative Medicine (1)
U.S.	$	8,510	7,818	8.9	%	8.9	-
International		5,980	5,913	1.1		6.4	(5.3)
		14,490	13,731	5.5		7.8	(2.3)

Innovative Medicine excluding COVID-19 Vaccine (1)
U.S.		8,510	7,818	8.9		8.9	-
International		5,808	5,628	3.2		8.7	(5.5)
		14,318	13,446	6.5		8.8	(2.3)
MedTech
U.S.		4,059	3,839	5.7		5.7	-
International		3,898	3,949	(1.3)		3.2	(4.5)
		7,957	7,788	2.2		4.4	(2.2)

U.S.		12,569	11,657	7.8		7.8	-
International		9,878	9,862	0.2		5.1	(4.9)
Worldwide		22,447	21,519	4.3		6.6	(2.3)
U.S.		12,569	11,657	7.8		7.8	-
International		9,706	9,577	1.3		6.4	(5.1)
Worldwide excluding COVID-19 Vaccine (1)	$	22,275	21,234	4.9	%	7.2	(2.3)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Refer to supplemental sales information schedules

SIX MONTHS

Percent Change

2024

2023

Total

Operations

Currency

$	16,122	14,841	8.6	%	8.6	-
	11,930	12,303	(3.0)		1.0	(4.0)
	28,052	27,144	3.3		5.2	(1.9)

	16,122	14,841	8.6		8.6	-
	11,733	11,271	4.1		8.5	(4.4)
	27,855	26,112	6.7		8.6	(1.9)
	8,067	7,598	6.2		6.2	-
	7,711	7,671	0.5		4.6	(4.1)
	15,778	15,269	3.3		5.4	(2.1)

	24,189	22,439	7.8		7.8	-
	19,641	19,974	(1.7)		2.4	(4.1)
	43,830	42,413	3.3		5.2	(1.9)
	24,189	22,439	7.8		7.8	-
	19,444	18,942	2.7		6.9	(4.2)
$	43,633	41,381	5.4	%	7.4	(2.0)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)				SECOND QUARTER
						Percent Change
		2024	2023	Total		Operations	Currency
Sales to customers by
geographic area
U.S.	$	12,569	11,657	7.8	%	7.8	-
Europe		5,214	5,131	1.6		3.4	(1.8)
Western Hemisphere excluding U.S.		1,212	1,136	6.7		22.6	(15.9)
Asia-Pacific, Africa		3,452	3,595	(4.0)		1.9	(5.9)
International		9,878	9,862	0.2		5.1	(4.9)
Worldwide	$	22,447	21,519	4.3	%	6.6	(2.3)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)				SECOND QUARTER
						Percent Change
		2024	2023	Total		Operations	Currency
Sales to customers by
geographic area (ex. COVID-19 Vaccine)
U.S.*	$	12,569	11,657	7.8	%	7.8	-
Europe(1)		5,042	4,846	4.1		6.0	(1.9)
Western Hemisphere excluding U.S.*		1,212	1,136	6.7		22.6	(15.9)
Asia-Pacific, Africa*		3,452	3,595	(4.0)		1.9	(5.9)
International		9,706	9,577	1.3		6.4	(5.1)
Worldwide	$	22,275	21,234	4.9	%	7.2	(2.3)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Refer to supplemental sales information schedules *No COVID-19 Vaccine sales

SIX MONTHS

					Percent Change
	2024	2023	Total		Operations	Currency
$	24,189	22,439	7.8	%	7.8	-
	10,377	10,721	(3.2)		(2.4)	(0.8)
	2,406	2,212	8.8		21.9	(13.1)
	6,858	7,041	(2.6)		3.4	(6.0)
	19,641	19,974	(1.7)		2.4	(4.1)
$	43,830	42,413	3.3	%	5.2	(1.9)

SIX MONTHS

					Percent Change
	2024	2023	Total		Operations	Currency
$	24,189	22,439	7.8	%	7.8	-
	10,180	9,689	5.1		6.0	(0.9)
	2,406	2,212	8.8		21.9	(13.1)
	6,858	7,041	(2.6)		3.4	(6.0)
	19,444	18,942	2.7		6.9	(4.2)
$	43,633	41,381	5.4	%	7.4	(2.0)

INNOVATIVE MEDICINE SEGMENT (2)

IMMUNOLOGY

Intl

REMICADE

US Exports (3)

Intl

SIMPONI / SIMPONI ARIA

Intl

STELARA

Intl

TREMFYA

Intl

OTHER IMMUNOLOGY

Intl

INFECTIOUS DISEASES

Intl

COVID-19 VACCINE

Intl

EDURANT / rilpivirine

Intl

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZAUS

Intl

OTHER INFECTIOUS DISEASES

Intl

REPORTED SALES vs. PRIOR PERIOD ($MM)

						SECOND QUARTER
							% Change
		2024	2023		Reported	Operational (1)	Currency
$	2,978	2,865	4.0%	4.0%	-
		1,744		1,631		6.9%	13.2%	-6.3%
		4,722	4,496	5.0%	7.3%	-2.3%
		231	277	-16.7%	-16.7%	-
		35	33	7.9%	7.9%	-
		127		152		-16.6%	-12.0%	-4.6%
		393	462	-14.9%	-13.4%	-1.5%
		267	285	-6.3%	-6.3%	-
		270		244		10.9%	22.8%	-11.9%
		537	529	1.6%	7.1%	-5.5%
		1,855	1,817	2.1%	2.1%	-
		1,030		981		5.0%	10.1%	-5.1%
		2,885	2,797	3.1%	4.9%	-1.8%
		589	450	30.8%	30.8%	-
		317		255		23.9%	30.5%	-6.6%
		906	706	28.3%	30.7%	-2.4%
		2	4	-51.5%	-51.5%	-
		0		0		-	-	-
		2	4	-51.5%	-51.5%	-
		334	395	-15.4%	-15.4%	-
		631		727		-13.1%	-11.6%	-1.5%
		965	1,121	-13.9%	-12.9%	-1.0%
		0	0	-	-	-
		172		285		-39.7%	-39.7%	0.0%
		172	285	-39.7%	-39.7%	0.0%
		8	8	-2.8%	-2.8%	-
		288		258		11.5%	13.0%	-1.5%
		297	266	11.0%	12.5%	-1.5%
		321	382	-16.0%	-16.0%	-
		117		109		6.5%	9.9%	-3.4%
		438	491	-11.0%	-10.3%	-0.7%
		5	5	18.5%	18.5%	-
		55		74		-25.6%	-21.1%	-4.5%
		61	79	-23.1%	-18.8%	-4.3%

REPORTED SALES vs. PRIOR PERIOD ($MM)

						SIX MONTHS
							% Change
		2024	2023		Reported	Operational (1)	Currency
$	5,431	5,313	2.2%	2.2%	-
		3,538		3,295		7.4%	12.1%	-4.7%
		8,969	8,608	4.2%	6.0%	-1.8%
		497	553	-10.1%	-10.1%	-
		62	74	-15.4%	-15.4%	-
		268		322		-16.9%	-13.2%	-3.7%
		827	949	-12.9%	-11.6%	-1.3%
		521	556	-6.2%	-6.2%	-
		569		510		11.7%	21.3%	-9.6%
		1,091	1,066	2.3%	7.0%	-4.7%
		3,251	3,268	-0.5%	-0.5%	-
		2,085		1,974		5.6%	9.1%	-3.5%
		5,336	5,241	1.8%	3.1%	-1.3%
		1,098	856	28.2%	28.2%	-
		616		489		25.8%	31.0%	-5.2%
		1,714	1,346	27.3%	29.2%	-1.9%
		2	7	-75.4%	-75.4%	-
		0		0		-	-	-
		2	7	-75.4%	-75.4%	-
		658	787	-16.4%	-16.4%	-
		1,128		1,920		-41.3%	-40.7%	-0.6%
		1,786	2,707	-34.0%	-33.7%	-0.3%
		0	0	-	-	-
		197		1,032		-80.9%	-80.9%	0.0%
		197	1,032	-80.9%	-80.9%	0.0%
		16	17	-7.0%	-7.0%	-
		603		529		14.1%	14.4%	-0.3%
		620	546	13.4%	13.7%	-0.3%
		635	760	-16.5%	-16.5%	-
		221		208		6.0%	7.8%	-1.8%
		856	968	-11.6%	-11.2%	-0.4%
		7	10	-29.4%	-29.4%	-
		107		151		-29.3%	-26.0%	-3.3%
		114	161	-29.3%	-26.2%	-3.1%

NEUROSCIENCE

Intl

CONCERTA / Methylphenidate

Intl

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTAUS

Intl

SPRAVATO

Intl

OTHER NEUROSCIENCE

Intl

ONCOLOGY

Intl

CARVYKTI

Intl

DARZALEX

Intl

ERLEADA

Intl

IMBRUVICA

Intl

TECVAYLI

Intl

ZYTIGA / abiraterone acetate

Intl

OTHER ONCOLOGY

Intl

REPORTED SALES vs. PRIOR PERIOD ($MM)

					SECOND QUARTER
						% Change
2024	2023		Reported	Operational (1)	Currency
1,102	1,029	7.1%	7.1%	-
	679		764		-11.1%	-6.0%	-5.1%
1,782	1,793	-0.6%	1.5%	-2.1%
34	64	-47.7%	-47.7%	-
	129		143		-9.8%	-4.6%	-5.2%
163	208	-21.5%	-17.9%	-3.6%
784	721	8.8%	8.8%	-
	269		310		-13.1%	-9.0%	-4.1%
1,054	1,031	2.2%	3.5%	-1.3%
226	144	57.9%	57.9%	-
	44		25		73.5%	77.4%	-3.9%
271	169	60.2%	60.8%	-0.6%
57	100	-42.5%	-42.5%	-
	237		286		-17.0%	-10.8%	-6.2%
294	386	-23.7%	-19.1%	-4.6%
2,636	2,069	27.4%	27.4%	-
	2,455		2,329		5.4%	10.8%	-5.4%
5,090	4,398	15.7%	18.6%	-2.9%
167	114	46.5%	46.5%	-
	20		3		*	*	*
186	117	59.8%	59.9%	-0.1%
1,641	1,322	24.2%	24.2%	-
	1,237		1,110		11.5%	17.9%	-6.4%
2,878	2,431	18.4%	21.3%	-2.9%
318	241	32.2%	32.2%	-
	418		326		28.0%	32.8%	-4.8%
736	567	29.8%	32.5%	-2.7%
246	262	-6.4%	-6.4%	-
	525		579		-9.4%	-5.6%	-3.8%
770	841	-8.5%	-5.9%	-2.6%
104	82	27.5%	27.5%	-
	30		12		*	*	*
135	94	42.9%	43.5%	-0.6%
11	9	21.6%	21.6%	-
	154		218		-29.6%	-23.6%	-6.0%
165	227	-27.7%	-21.9%	-5.8%
148	40	*	*	-
	71		80		-10.4%	-6.0%	-4.4%
221	120	84.2%	87.2%	-3.0%

REPORTED SALES vs. PRIOR PERIOD ($MM)

					SIX MONTHS
						% Change
2024	2023		Reported	Operational (1)	Currency
2,156	2,007	7.4%	7.4%	-
	1,428		1,590		-10.2%	-5.2%	-5.0%
3,585	3,597	-0.3%	1.9%	-2.2%
75	134	-44.3%	-44.3%	-
	265		279		-5.1%	-0.2%	-4.9%
340	414	-17.8%	-14.5%	-3.3%
1,549	1,434	8.0%	8.0%	-
	561		641		-12.4%	-8.8%	-3.6%
2,110	2,075	1.7%	2.8%	-1.1%
417	255	63.9%	63.9%	-
	78		45		74.6%	76.3%	-1.7%
496	300	65.5%	65.7%	-0.2%
115	184	-37.3%	-37.3%	-
	524		625		-16.2%	-9.5%	-6.7%
639	809	-21.0%	-15.8%	-5.2%
5,019	3,958	26.8%	26.8%	-
	4,885		4,552		7.3%	11.7%	-4.4%
9,904	8,510	16.4%	18.7%	-2.3%
307	184	66.8%	66.8%	-
	36		5		*	*	*
343	189	81.5%	81.5%	0.0%
3,105	2,513	23.6%	23.6%	-
	2,465		2,182		12.9%	18.4%	-5.5%
5,570	4,695	18.6%	21.2%	-2.6%
603	490	23.0%	23.0%	-
	822		619		32.8%	36.5%	-3.7%
1,425	1,109	28.4%	30.5%	-2.1%
511	532	-3.9%	-3.9%	-
	1,043		1,136		-8.3%	-5.6%	-2.7%
1,554	1,668	-6.9%	-5.1%	-1.8%
205	139	47.7%	47.7%	-
	63		18		*	*	*
268	157	70.2%	70.2%	0.0%
20	25	-19.7%	-19.7%	-
	326		447		-27.2%	-22.1%	-5.1%
346	472	-26.8%	-22.0%	-4.8%
267	75	*	*	-
	131		144		-8.5%	-5.8%	-2.7%
399	219	82.4%	84.2%	-1.8%

PULMONARY HYPERTENSION

Intl

OPSUMIT

Intl

UPTRAVI

Intl

OTHER PULMONARY HYPERTENSIONUS

Intl

CARDIOVASCULAR / METABOLISM / OTHERUS

Intl

XARELTO

Intl

OTHER

Intl

TOTAL INNOVATIVE MEDICINE

Intl

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD ($MM)

						SECOND QUARTER
							% Change
		2024	2023		Reported	Operational (1)	Currency
		743	684		8.7%	8.7%	-
		296		289		2.6%	11.2%	-8.6%
		1,039	972		6.9%	9.4%	-2.5%
		373	328		13.7%	13.7%	-
		170		179		-5.0%	0.5%	-5.5%
		544	507		7.1%	9.1%	-2.0%
		349	338		3.3%	3.3%	-
		76		61		24.6%	34.4%	-9.8%
		426	399		6.6%	8.1%	-1.5%
		20	18		18.8%	18.8%	-
		50		48		3.1%	21.0%	-17.9%
		71	66		7.2%	20.4%	-13.2%
		717	776		-7.7%	-7.7%	-
		176		174		0.6%	4.0%	-3.4%
		892	950		-6.2%	-5.5%	-0.7%
		587	637		-7.9%	-7.9%	-
		-		-		-	-	-
		587	637		-7.9%	-7.9%	-
		129	138		-6.4%	-6.4%	-
		176		174		0.6%	4.0%	-3.4%
		305	313		-2.5%	-0.6%	-1.9%
		8,510	7,818		8.9%	8.9%	-
		5,980		5,913		1.1%	6.4%	-5.3%
$	14,490	13,731		5.5%	7.8%	-2.3%

REPORTED SALES vs. PRIOR PERIOD ($MM)

						SIX MONTHS
							% Change
		2024	2023		Reported	Operational (1)	Currency
		1,509	1,284		17.5%	17.5%	-
		579		561		3.4%	11.0%	-7.6%
		2,088	1,844		13.2%	15.5%	-2.3%
		729	601		21.3%	21.3%	-
		339		346		-2.2%	2.5%	-4.7%
		1,068	947		12.7%	14.4%	-1.7%
		741	642		15.5%	15.5%	-
		152		119		27.6%	36.4%	-8.8%
		894	761		17.4%	18.7%	-1.3%
		38	41		-6.1%	-6.1%	-
		89		95		-6.7%	10.2%	-16.9%
		127	136		-6.5%	5.3%	-11.8%
		1,348	1,491		-9.6%	-9.6%	-
		373		386		-3.6%	-1.9%	-1.7%
		1,721	1,877		-8.3%	-8.0%	-0.3%
		1,105	1,215		-9.1%	-9.1%	-
		-		-		-	-	-
		1,105	1,215		-9.1%	-9.1%	-
		243	275		-11.8%	-11.8%	-
		373		386		-3.6%	-1.9%	-1.7%
		616	662		-7.0%	-6.0%	-1.0%
		16,122	14,841		8.6%	8.6%	-
		11,930		12,303		-3.0%	1.0%	-4.0%
$	28,052	27,144		3.3%	5.2%	-1.9%

MEDTECH SEGMENT (2)

CARDIOVASCULAR (4)

Intl

WW ELECTROPHYSIOLOGYUS

Intl

ABIOMED

Intl

SHOCKWAVE (5)

Intl

OTHER CARDIOVASCULAR (4)US

Intl

ORTHOPAEDICS

Intl

HIPS

Intl

KNEES

Intl

TRAUMA

Intl

SPINE, SPORTS & OTHERUS

Intl

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

						% Change
	2024	2023		Reported	Operational (1)	Currency
$	1,119	908	23.3%	23.3%	-
	753		712		5.7%	11.2%	-5.5%
	1,873	1,620	15.6%	18.0%	-2.4%
	705	609	15.7%	15.7%	-
	618		587		5.4%	11.1%	-5.7%
	1,323	1,196	10.6%	13.4%	-2.8%
	309	272	13.2%	13.2%	-
	72		59		20.7%	25.3%	-4.6%
	379	331	14.5%	15.4%	-0.9%
	77	-	*	*	-
	0		-		-	-	-
	77	-	*	*	-
	29	27	12.5%	12.5%	-
	64		67		-4.5%	-1.0%	-3.5%
	93	93	0.3%	2.8%	-2.5%
	1,422	1,388	2.5%	2.5%	-
	890		878		1.4%	4.5%	-3.1%
	2,312	2,265	2.1%	3.3%	-1.2%
	265	250	5.8%	5.8%	-
	152		147		3.4%	6.8%	-3.4%
	417	397	4.9%	6.2%	-1.3%
	230	221	4.2%	4.2%	-
	163		142		14.9%	17.7%	-2.8%
	394	363	8.4%	9.5%	-1.1%
	498	483	3.0%	3.0%	-
	260		255		2.4%	5.5%	-3.1%
	759	739	2.8%	3.8%	-1.0%
	430	433	-0.8%	-0.8%	-
	314		334		-6.1%	-2.9%	-3.2%
	743	766	-3.1%	-1.7%	-1.4%

REPORTED SALES vs. PRIOR PERIOD ($MM)

SIX MONTHS

						% Change
	2024	2023		Reported	Operational (1)	Currency
$	2,144	1,771	21.1%	21.1%	-
	1,534		1,352		13.4%	18.9%	-5.5%
	3,679	3,123	17.8%	20.2%	-2.4%
	1,397	1,180	18.4%	18.4%	-
	1,270		1,109		14.6%	20.4%	-5.8%
	2,667	2,288	16.5%	19.4%	-2.9%
	612	536	14.1%	14.1%	-
	139		119		16.5%	20.0%	-3.5%
	750	655	14.5%	15.2%	-0.7%
	77	-	*	*	-
	0		-		-	-	-
	77	-	*	*	-
	59	55	7.7%	7.7%	-
	126		125		0.8%	4.8%	-4.0%
	185	180	2.9%	5.7%	-2.8%
	2,870	2,751	4.3%	4.3%	-
	1,782		1,759		1.3%	3.6%	-2.3%
	4,652	4,510	3.2%	4.0%	-0.8%
	535	491	8.9%	8.9%	-
	304		296		2.6%	5.0%	-2.4%
	839	787	6.5%	7.4%	-0.9%
	472	447	5.5%	5.5%	-
	323		284		13.6%	15.4%	-1.8%
	795	731	8.7%	9.4%	-0.7%
	1,002	974	2.9%	2.9%	-
	521		522		0.0%	2.1%	-2.1%
	1,524	1,496	1.9%	2.6%	-0.7%
	862	839	2.7%	2.7%	-
	634		657		-3.5%	-1.0%	-2.5%
	1,495	1,495	0.0%	1.1%	-1.1%

SURGERY

Intl

ADVANCED

Intl

GENERAL

Intl

VISION

Intl

CONTACT LENSES / OTHERUS

Intl

SURGICAL

Intl

TOTAL MEDTECH

Intl

REPORTED SALES vs. PRIOR PERIOD ($MM)

							SECOND QUARTER
								% Change
		2024			2023		Reported	Operational (1)	Currency
		995			1,015	-2.0%	-2.0%	-
		1,493			1,580		-5.5%	-0.7%	-4.8%
		2,488			2,594	-4.1%	-1.2%	-2.9%
		466			466	0.1%	0.1%	-
		675			757		-10.8%	-6.4%	-4.4%
		1,141			1,222	-6.7%	-3.9%	-2.8%
		528			548	-3.7%	-3.7%	-
		818			823		-0.7%	4.5%	-5.2%
		1,346			1,372	-1.9%	1.2%	-3.1%
		523			529	-1.2%	-1.2%	-
		763			778		-2.0%	2.2%	-4.2%
		1,285			1,308	-1.7%	0.8%	-2.5%
		409			409	0.2%	0.2%	-
		509			530		-4.0%	1.2%	-5.2%
		918			939	-2.2%	0.7%	-2.9%
		113			120	-5.8%	-5.8%	-
		254			249		2.1%	4.5%	-2.4%
		367			369	-0.5%	1.2%	-1.7%
		4,059			3,839	5.7%	5.7%	-
		3,898			3,949		-1.3%	3.2%	-4.5%
$	7,957	$	7,788	2.2%	4.4%	-2.2%

REPORTED SALES vs. PRIOR PERIOD ($MM)

						SIX MONTHS
							% Change
		2024	2023		Reported	Operational (1)	Currency
		1,982	1,990	-0.4%	-0.4%	-
		2,922		3,039		-3.8%	0.7%	-4.5%
		4,904	5,028	-2.5%	0.3%	-2.8%
		912	910	0.2%	0.2%	-
		1,316		1,430		-8.0%	-3.7%	-4.3%
		2,228	2,340	-4.8%	-2.2%	-2.6%
		1,070	1,079	-0.9%	-0.9%	-
		1,606		1,608		-0.2%	4.7%	-4.9%
		2,676	2,688	-0.5%	2.4%	-2.9%
		1,070	1,087	-1.5%	-1.5%	-
		1,473		1,521		-3.2%	0.6%	-3.8%
		2,543	2,608	-2.5%	-0.3%	-2.2%
		847	853	-0.6%	-0.6%	-
		981		1,039		-5.6%	-0.9%	-4.7%
		1,828	1,892	-3.4%	-0.8%	-2.6%
		223	234	-4.8%	-4.8%	-
		492		482		2.1%	4.0%	-1.9%
		715	716	-0.1%	1.1%	-1.2%
		8,067	7,598	6.2%	6.2%	-
		7,711		7,671		0.5%	4.6%	-4.1%
$	15,778	15,269	3.3%	5.4%	-2.1%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

* Percentage greater than 100% or not meaningful

Operational growth excludes the effect of translational currency
Unaudited
Reported as U.S. sales
Previously referred to as Interventional Solutions
Acquired on May 31, 2024

Supplemental Sales Information (Unaudited)

(Dollars in Millions)

			SECOND QUARTER
					Percent Change
		2024	2023	Total		Operations	Currency
Innovative Medicine
U.S.	$	8,510	7,818	8.9	%	8.9	-
International		5,980	5,913	1.1		6.4	(5.3)
Worldwide		14,490	13,731	5.5		7.8	(2.3)

COVID-19 Vaccine
U.S.		-	-	-		-	-
International		172	285	(39.7)		(39.7)	0.0
Worldwide		172	285	(39.7)		(39.7)	0.0

Innovative Medicine excluding COVID-19 Vaccine
U.S.		8,510	7,818	8.9		8.9	-
International		5,808	5,628	3.2		8.7	(5.5)
Worldwide		14,318	13,446	6.5		8.8	(2.3)
Worldwide
U.S.		12,569	11,657	7.8		7.8	-
International		9,878	9,862	0.2		5.1	(4.9)
Worldwide		22,447	21,519	4.3		6.6	(2.3)
COVID-19 Vaccine
U.S.		-	-	-		-	-
International		172	285	(39.7)		(39.7)	0.0
Worldwide		172	285	(39.7)		(39.7)	0.0

Worldwide
U.S.		12,569	11,657	7.8		7.8	-
International		9,706	9,577	1.3		6.4	(5.1)
Worldwide excluding COVID-19 Vaccine	$	22,275	21,234	4.9	%	7.2	(2.3)

SIX MONTHS

			Percent Change
	2024	2023	Total		Operations	Currency
$	16,122	14,841	8.6	%	8.6	-
	11,930	12,303	(3.0)		1.0	(4.0)
	28,052	27,144	3.3		5.2	(1.9)

	-	-	-		-	-
	197	1,032	(80.9)		(80.9)	0.0
	197	1,032	(80.9)		(80.9)	0.0

	16,122	14,841	8.6		8.6	-
	11,733	11,271	4.1		8.5	(4.4)
	27,855	26,112	6.7		8.6	(1.9)
	24,189	22,439	7.8		7.8	-
	19,641	19,974	(1.7)		2.4	(4.1)
	43,830	42,413	3.3		5.2	(1.9)
	-	-	-		-	-
	197	1,032	(80.9)		(80.9)	0.0
	197	1,032	(80.9)		(80.9)	0.0

	24,189	22,439	7.8		7.8	-
	19,444	18,942	2.7		6.9	(4.2)
$	43,633	41,381	5.4	%	7.4	(2.0)

Europe	$	5,214	5,131	1.6	%	3.4	(1.8)	$	10,377	10,721	(3.2)	%	(2.4)	(0.8)
Europe COVID-19 Vaccine Sales		172	285	(39.7)		(39.7)	0.0			197	1,032	(80.9)		(80.9)	0.0
Europe excluding COVID-19 Vaccine Sales	$	5,042	4,846	4.1	%	6.0	(1.9)	$	10,180	9,689	5.1	%	6.0	(0.9)

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)				SECOND QUARTER
		2024				2023		Percent
			Percent				Percent	Increase
	Amount	to Sales		Amount	to Sales	(Decrease)
Sales to customers	$	22,447	100.0	$	21,519	100.0	4.3
Cost of products sold		6,869	30.6			6,462	30.0	6.3
Gross Profit		15,578	69.4			15,057	70.0	3.5
Selling, marketing and administrative expenses		5,681	25.3			5,396	25.1	5.3
Research and development expense		3,440	15.3			3,703	17.2	(7.1)
In-process research and development impairments		194	0.9			-	0.0
Interest (income) expense, net		(125)	(0.6)			(109)	(0.5)
Other (income) expense, net		653	2.9			(384)	(1.8)
Restructuring		(13)	0.0			145	0.7
Earnings before provision for taxes on income		5,748	25.6			6,306	29.3	(8.8)
Provision for taxes on income		1,062	4.7			930	4.3	14.2
Net earnings from Continuing Operations	$	4,686	20.9	$	5,376	25.0	(12.8)

Net earnings/(loss) from Discontinued Operations, net of tax		-				(232)
Net earnings	$	4,686		$	5,144
Net earnings per share (Diluted) from Continuing Operations	$	1.93		$	2.05		(5.9)
Net earnings/(loss) per share (Diluted) from Discontinued Operations	$	-		$	(0.09)
Average shares outstanding (Diluted)		2,422.0				2,625.7
Effective tax rate from Continuing Operations		18.5 %				14.7 %

Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations	$	8,404	37.4	$	8,005	37.2	5.0
Net earnings from Continuing Operations	$	6,840	30.5	$	6,730	31.3	1.6
Net earnings per share (Diluted) from Continuing Operations	$	2.82		$	2.56		10.2
Effective tax rate from Continuing Operations		18.6 %				15.9 %

(1) See Reconciliation of Non-GAAP Financial Measures.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Johnson & Johnson published this content on 17 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 July 2024 10:29:08 UTC.

Latest news about Johnson & Johnson

Dow Closes at Record, Nasdaq Slides as Markets Parse Fed Governor Remarks, Earnings	10:05pm	MT
Dow Closes at Record High as Nasdaq Plunges; Markets Parse Fed Governor Remarks, Earnings, Trade Threats	09:28pm	MT
Sector Update: Health Care Stocks Advance Late Afternoon	08:59pm	MT
Fed Governor's Remarks, Earnings Leave Equities Mixed	08:50pm	MT
Stifel Raises Johnson & Johnson's Price Target to $160 From $155	07:54pm	MT
Nasdaq plunges, hit by tumbling chips, megacaps; Dow extends rally	07:44pm	RE
Sector Update: Health Care Stocks Higher Wednesday Afternoon	07:02pm	MT
Sector Update: Health Care	06:57pm	MT
Fed Governor Waller's Comments, Earnings Leave Equities Mixed; Nvidia Slides	06:28pm	MT
Megacap tech, chip stock rout drags Nasdaq to two-week low; Dow outperforms	05:49pm	RE
Global markets live: Adidas, TSMC, Vale, HSBC, J&J...	05:24pm
Top Midday Stories: Chip Stocks Fall; MBA US Mortgage Applications Rebound; Johnson & Johnson, Elevance Health Q2 Earnings Rise; Prologis Posts Q2 Beat; VF to Sell Supreme Brand to EssilorLuxottica	05:03pm	MT
Stocks in motion: VF Corp and Johnson & Johnson stand out	04:39pm
Trending : Johnson & Johnson Beats 2Q Sales Guidance	03:15pm	DJ
Johnson & Johnson Cuts Full-Year Earnings Outlook Following Second-Quarter Beat	02:53pm	MT
Earnings reports take center stage as tech stocks tumble	02:38pm
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	02:25pm	MT
Wall Street set to fall as megacap chip, tech stocks tumble	02:14pm	RE
Transcript : Johnson & Johnson, Q2 2024 Earnings Call, Jul 17, 2024	01:30pm
Genmab, J&J Log Higher Q2 Sales for Blood Cancer Drug Darzalex	12:27pm	MT
Stock Futures Decline as Traders Await More Earnings; Asia, Europe Churn	12:26pm	MT
Johnson & Johnson Maintains Quarterly Dividend at $1.24 per Share, Payable Sept. 10 to Shareholders of Record on Aug. 27	12:21pm	MT
J&J: Quarterly adjusted EPS up 10.2	12:03pm	CF
Johnson & Johnson Q2 Adjusted Earnings, Revenue Rise; Lowers Full-Year Earnings Guidance	11:49am	MT
Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024	11:25am	CI

Chart Johnson & Johnson

Duration

Period

More charts

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).

Sector

Pharmaceuticals

Calendar

11:45am - Q2 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm

More Strategies

Ratings for Johnson & Johnson

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

151 USD

Average target price

171.5 USD

Spread / Average Target

+13.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOHNSON & JOHNSON	-0.10%	363B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B
SANOFI	+2.52%	125B

Other Pharmaceuticals

Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Johnson & Johnson : Second Quarter 2024 2Q24 Other Financial Disclosures

EPS Revisions